|
|
 |
|
Viewing report
|
|
|
|
Ranbaxy Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 24
Ranbaxy is India’s leading pharmaceutical company, one of only a handful so far to achieve international prominence. Manufacturing is conducted mainly in India, but also in other countries.
In June 2008, in a surprise move, Daiichi Sankyo announced plans to acquire Ranbaxy in a deal which valued Ranbaxy at US$8.5 billion. The acquisition was completed in October 2008. As a result, the two firms are undergoing a reorganisation process to combine their strengths.
In 2004, revenues broke the US$1 billion mark for the first time. In 2009, Ranbaxy recorded total consolidated revenues worth Rs80,837.0 million (US$1,670.9 million). Profit after tax reached Rs2,964.9 million (US$61.3 million), compared to a loss of Rs9,512.1 million in 2008.
The company claims its long term aim is to move away from generics and into original drug research. This is partly spurred by the tightening of India’s patent laws which began in 2005. The firm is undertaking research into a new anti-malarial product.
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
|
|
|
|
